ERBB2 and carcinoma: In all, 10 out of 19 (52.6%) carcinomas with an overexpression of HER2 protein showed an immunohistochemical loss of PTEN in comparison with 17.5% (38 out of 217) PTEN negativity in HER2-negative tumours (P<0.001).